Company / Financials
Rani Therapeutics Holdings, Inc. Financials
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.0M
FY2025
Net Income
-$30.0M
FY2025 · +11.6% YoY
Profit Margin
-2920.0%
FY2025 · net income / revenue
ROE
-90.9%
FY2025 · return on equity
Total Assets
$58.6M
FY2025
Total Debt
-
FY2025
Equity
$33.0M
FY2025
ROA
-51.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.0MNet Income HistoryProfit after all expenses and taxes-$30.0M+11.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$53.3M+19.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$23.9M-9.6% YoYR&D Expense HistoryResearch and development spending$26.7M-32.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$5.0M-1.0% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$1.05+21.1% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$1.05+21.1% YoYShares Outstanding HistoryWeighted average diluted shares outstanding28.5K+11.6% YoY